Figure 2.

Estimated annualized rates of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia over 6 months of treatment with Gla‐300 or Gla‐100 in the T2DM EDITION 1, 2 and 3 studies, as a function of HbA1c at Month 6. Modified intent‐to‐treat population. Glucose‐lowering therapy at screening: EDITION 1, basal insulin + mealtime insulin ± metformin; EDITION 2, basal insulin + OADs; EDITION 3, OADs (insulin‐naïve). Abbreviations: Gla‐100, insulin glargine 100 U/mL; Gla‐300, insulin glargine 300 U/mL; HbA1c, glycated haemoglobin; OAD, oral antihyperglycaemic drug; T2DM, type 2 diabetes mellitus